Results 201 to 210 of about 2,182,759 (269)

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

DEVELOPMENT AND OPTIMIZATION OF RABEPRAZOLE CHRONO-MODULATED DRUG DELIVERY SYSTEMS

Phaneendra Kurapati, Santhivardhan Chinni   +1 more
openalex   +2 more sources

Stability indicating RP-HPLC method development and validation for the determination of Acalabrutinib in bulk drug and capsule dosage form

, 2019
A Anusha, P. Harsha Latha, Uttam Prasad Panigrahy, T. Rama Mohan Reddy, K Abbulu   +4 more
openalex   +2 more sources

Genetic Variations in the P2X7 Receptor: Opportunities and Challenges for Drug Development. [PDF]

Int J Mol Sci
Cheah JSY, Skarratt KK, Fuller SJ, Balle T.   +3 more
europepmc   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Comprehensive Review on Phage Therapy and Phage-Based Drug Development

Longzhu Cui, Shinya Watanabe, Kazuhiko Miyanaga, Kotaro Kiga, Teppei Sasahara, Yoshifumi Aiba, Xin-Ee Tan, Srivani Veeranarayanan, Kanate Thitiananpakorn, Huong Minh Nguyen, Dhammika Leshan Wannigama   +10 more
openalex   +2 more sources

DEVELOPMENT AND VLAIDATION OF SIMPLE UV-SPECTROPHOTOMETRIC METHOD OF QUANTIZATION OF DIAZEPAM IN BULK DRUG AND SOLID DOSAGE FORMULATION USING MIXED SOLVENCY CONCEPT

, 2017
Sanjay Jain, R. K. Maheshwari, Rajeev Nema, Indrajeet Singhvi   +3 more
openalex   +2 more sources

Genetic evidence informs the direction of therapeutic modulation in drug development. [PDF]

NPJ Drug Discov
Chen R, Duffy Á, Park JK, Stein D, Schlessinger A, Itan Y, Glicksberg BS, Tinker RJ, Jordan DM, Rocheleau G, Do R.   +10 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Harnessing Organoid Platforms for Nanoparticle Drug Development. [PDF]

Drug Des Devel Ther
Chen L, Luo X, Zhang J, Zhang J, Yang C, Zhao Y.   +5 more
europepmc   +1 more source